Hospital-Treated Gram-Positive Infections – Epidemiology – Mature markets

Clarivate Epidemiology’s coverage of hospital-treated gram-positive infections (HT–GPIs) comprises epidemiological estimates of nine types of infections—urinary tract infections (UTIs), bloodstream infections (BSIs), complicated intra-abdominal infections (cIAIs), complicated skin and skin structure infections (cSSSIs), surgical-site infections (SSIs), nosocomial pneumonia (NP), hospital-acquired pneumonia (HAP), healthcare-acquired pneumonia (HCAP), and ventilator-associated pneumonia (VAP)—in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of HT–GPIs for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s HT–GPI forecast will answer the following questions:

• Of all people with HT–GPIs, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HT–GPIs over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 42 HT–GPI patient populations, including the following:

• Diagnosed gram-positive HCAP hospitalization events due to Enterococcus spp.
• Diagnosed gram-positive HAP hospitalization events due to CoNS.
• Diagnosed gram-positive SSI hospitalization events due to S. aureus.
• Diagnosed gram-positive UTI hospitalization events due to other gram-positive bacteria
• Diagnosed gram-positive BSI hospitalization events due to Enterococcus spp.
• Diagnosed gram-positive cIAI hospitalization events due to S. aureus.
• Diagnosed gram-positive cSSSI hospitalization events due to CoNS.
• Diagnosed gram-positive VAP hospitalization events due to S. aureus.

Note: Coverage may vary by country and region.